Diagnostic solutions manufacturer MaximBio has received a new contract from the National Institutes of Health (NIH) for the development of a Covid-19 and Influenza A/B combo test.
The contract was awarded under the NIH’s Rapid Acceleration of Diagnostics (RADx) initiative, which was established to encourage organisations to speed up innovation in the development, commercialisation and implementation of diagnostic technologies for Covid-19 testing.
The new contract agreement builds on MaximBio’s collaboration with the NIH during the peak of the Covid-19 pandemic.
It is partially funded by the National Institute of Biomedical Imaging and Bioengineering, the NIH and the Department of Health and Human Services.
The company previously collaborated with the NIH to successfully launch the MaximBio ClearDetect Covid-19 Antigen Home Test.
The new Covid-19 and Influenza A/B combo test will use innovative lateral-flow assay (LFA) technology.
When combined with the FiarFly analyser platform and MaximBio’s manufacturing techniques, the LFA technology enables enhanced assay performance.
The FiarFly platform comprises a pocket-sized, battery-powered reader designed to bring diagnostic testing closer to the patient.
It provides performance similar to the lab but in the comfort of a home and in a cost-effective manner.
The easy-to-operate reader enables increased accessibility and provides results with higher sensitivity at a cost similar to visually read at-home tests.
The platform can be used to perform several tests on a single device. It comes with Health Insurance Portability and Accountability Act-compliant connectivity for reporting electronic medical record results.
In a recent interview, MaximBio chief operating officer Jonathan Maa stated that the new collaboration is backed by the company’s earlier success with RADx and expanded manufacturing capabilities in the US.
Maa said: “Our upgraded infrastructure allows us to produce in excess of 100 million tests annually, right here in the United States.
“We are looking forward to working again with the NIH on this exciting new project and the opportunity to offer the market an innovative, yet affordable, diagnostic platform to transform the future of at-home testing solutions.”